Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.12
-0.42 (-4.92%)
At close: Apr 10, 2026, 4:00 PM EDT
7.98
-0.14 (-1.72%)
Pre-market: Apr 13, 2026, 8:13 AM EDT
Novavax Revenue
In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. Novavax had revenue of $147.14M in the quarter ending December 31, 2025, with 66.61% growth.
Revenue (ttm)
$1.12B
Revenue Growth
+64.69%
P/S Ratio
1.18
Revenue / Employee
$1,499,972
Employees
749
Market Cap
1.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12B | 441.32M | 64.69% |
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | 34.29M | 3.11M | 9.98% |
| Dec 31, 2017 | 31.18M | 15.82M | 103.06% |
| Dec 31, 2016 | 15.35M | -20.90M | -57.65% |
| Dec 31, 2015 | 36.25M | 5.59M | 18.24% |
| Dec 31, 2014 | 30.66M | 9.74M | 46.59% |
| Dec 31, 2013 | 20.92M | -1.16M | -5.26% |
| Dec 31, 2012 | 22.08M | 7.39M | 50.30% |
| Dec 31, 2011 | 14.69M | 14.35M | 4,182.22% |
| Dec 31, 2010 | 343.00K | 18.00K | 5.54% |
| Dec 31, 2009 | 325.00K | -739.00K | -69.45% |
| Dec 31, 2008 | 1.06M | -449.00K | -29.68% |
| Dec 31, 2007 | 1.51M | -225.00K | -12.95% |
| Dec 31, 2006 | 1.74M | -3.61M | -67.47% |
| Dec 31, 2005 | 5.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Monte Rosa Therapeutics | 123.67M |
| Immatics | 56.67M |
| Wave Life Sciences | 42.73M |
| Taysha Gene Therapies | 9.77M |
| AtaiBeckley | 4.09M |
| Maze Therapeutics | 2.50M |
NVAX News
- 4 days ago - Novavax Faces Shareholder Revolt As Shah Capital Criticizes Strategy - Benzinga
- 5 days ago - Shah Capital intends to vote against Novavax's board nominees, executive compensation - Reuters
- 14 days ago - Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development - PRNewsWire
- 6 weeks ago - What's Going On With Novavax Stock On Friday? - Benzinga
- 6 weeks ago - Novavax to Participate in Upcoming Investor Conferences - PRNewsWire
- 6 weeks ago - COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb - Benzinga
- 6 weeks ago - Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals - Reuters
- 6 weeks ago - Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire